文献速递炎症性肠病

5-氨基水杨酸维持治疗并不优于不维持治疗:新诊断克罗恩病的全国性队列研究

5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-03-09

该研究利用以色列epi-IIRN队列2005至2020年新诊断克罗恩病患者数据,经倾向评分匹配比较一线5-氨基水杨酸维持治疗与不维持治疗的结局。匹配后两组在启用生物制剂、激素依赖、住院和克罗恩病相关手术时间上无显著差异,但5-ASA维持组急性肾损伤和胰腺炎发生率更高,匹配后不良事件发生率相似。

要点

  • 一线5-ASA单药维持治疗在结局上不优于不维持治疗。
  • 5-ASA维持组急性肾损伤(5.2% vs 3.3%,p<0.001)和胰腺炎(2.4% vs 1.8%,p=0.03)发生率更高。
  • 倾向评分匹配后两组不良事件发生率相似。

核心结论

  • 一线5-ASA单药治疗不优于不维持治疗,但与略高的不良事件发生率相关,且两种策略的使用率逐年下降。
  • 作者认为,这些发现提示部分轻度克罗恩病患者可考虑观察等待策略。

研究设计与样本

  • 利用epi-IIRN队列数据,纳入以色列2005至2020年间诊断的所有克罗恩病患者。
  • 采用倾向评分匹配比较5-ASA维持治疗组与不维持治疗组的结局。

主要发现

  • 在19,264例诊断克罗恩病的患者中,8610例(45%)符合入选标准,其中3027例(16%)接受5-ASA维持治疗,5583例(29%)未接受维持治疗。
  • 5-ASA维持治疗从2005年诊断患者的21%降至2019年的11%(p<0.001),不维持治疗从36%降至23%(p<0.001)。
  • 诊断后1年、3年和5年维持治疗的概率:5-ASA维持组分别为78%、57%和47%,不维持组分别为76%、49%和38%(p<0.001)。
  • 倾向评分分析成功匹配1993对治疗与未治疗患者,显示至生物制剂启用(p=0.2)、激素依赖(p=0.9)、住院(p=0.5)和克罗恩病相关手术(p=0.1)的时间结局相当。
  • 5-ASA维持组相比不维持组急性肾损伤(5.2% vs 3.3%;p<0.001)和胰腺炎(2.4% vs 1.8%;p=0.03)发生率更高,但倾向评分匹配后不良事件发生率相似。

临床怎么用

  • 作者认为,部分轻度克罗恩病患者可考虑观察等待策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 5-aminosalicylates (5-ASA) are widely used in Crohn's disease (CD) despite guidelines advising otherwise. We aimed to assess in nationwide study the outcomes of first-line 5-ASA maintenance therapy (5-ASA-MT) compared with no maintenance treatment (no-MT) in patients with newly diagnosed CD. METHODS: We utilised data from the epi-IIRN cohort, including all patients with CD diagnosed in Israel between 2005 and 2020. Propensity score (PS) matching was utilised to compare outcomes in the 5-ASA-MT versus no-MT groups. RESULTS: Of the 19,264 patients diagnosed with CD, 8610 (45%) fulfilled the eligibility criteria (3027 [16%] received 5-ASA-MT and 5583 [29%] received no-MT). Both strategies declined over the years; 5-ASA-MT from 21% of CD patients diagnosed in 2005 to 11% in 2019 (p < 0.001) and no-MT from 36% to 23% (p < 0.001). The probability of maintaining therapy at 1, 3 and 5 years from diagnosis: 5-ASA-MT-78%, 57% and 47% and no-MT-76%, 49% and 38% respectively (p < 0.001). PS analysis successfully matched 1993 pairs of treated and untreated patients and demonstrated comparable outcomes of time to: biologic (p = 0.2), steroid dependency (p = 0.9), hospitalisation (p = 0.5) and CD-related surgery (p = 0.1). Rates of acute kidney injury (5.2% vs. 3.3%; p < 0.001) and pancreatitis (2.4% vs. 1.8%; p = 0.03) were higher in the 5-ASA-MT group compared with the no-MT group but after PS matching the rates of adverse events were similar. CONCLUSION: First-line 5-ASA monotherapy was not superior to no-MT but associated with a slightly higher rates of adverse events, while both strategies have declined over the years. These findings suggest that a subset of patients with mild CD may be offered a watchful waiting approach.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Atia O, Goren I, Fischler TS, et al. 5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study. Aliment Pharmacol Ther. 2023. PMID: 36894866. doi:10.1111/apt.17419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。